LuminUltra Acquires Legionella Testing Business from Genomadix and Inks Strategic License to Commercialize Additional Tests for Ultra-portable Molecular Diagnostic Platform
9.9.2024 14:00:00 EEST | Business Wire | Press release
LuminUltra (luminultra.com), the global leader in applied molecular diagnostics, today announced the acquisition of the legionella testing business assets of Genomadix Inc (genomadix.com), along with rights to develop and commercialize further assays and test methods in water, energy and food and beverage markets globally using the Genomadix Cube™ qPCR (quantitative polymerase chain reaction) Platform.
With this transaction, LuminUltra further expands its industry-leading portfolio of molecular testing solutions for rapid identification and quantification of the microbes within residential, commercial and industrial water systems that are responsible for causing the potentially deadly Legionnaire’s disease.
When paired with its easy-to-use automated test kit, the Genomadix Cube thermocycling platform will generate results that measure the presence and quantity of Legionella contamination in under one hour with laboratory-grade sensitivity. The elegant simplicity of the system allows any user in the field to quickly and accurately assess the level of contamination within their water system and take the actions necessary to minimize risk of outbreaks and operational downtime.
The industry leading legionella detection toolkit
“With this latest addition to our portfolio, we can now help even more customers around the world to rapidly and accurately monitor and manage against the proliferation of harmful Legionella bacteria,” said Pat Whalen, LuminUltra CEO. “This rapid, point of use solution complements our existing GeneCount® laboratory qPCR workflow and mail-in sample testing offerings by providing a best-in-class solution for those time sensitive, ‘in-field’ use cases that demand near-real-time and accurate results to confidently inform critical operational decisions and actions.”
Steve Edgett, CEO of Genomadix, added, “LuminUltra was the perfect home for the Legionella business that we nurtured under the Spartan Bioscience brand. We intend to support a seamless transition with our customers. We are thrilled that LuminUltra will bring scale, expertise, and focus to the Legionella business. Genomadix is focused on the development and commercialization of precision medicine tests on the Cube and licensing our CubeX Open Platform to strategic partners. This agreement is a win-win as LuminUltra will lead the development of new tests and expanded access to fast and accurate qPCR testing on CubeX for time-sensitive point of use applications in applied markets.”
The transaction was completed on July 31, 2024.
About LuminUltra
Founded in 1995, LuminUltra is a biological diagnostic testing company headquartered in Canada with operations in six countries. Widely recognized as the global leader in applied molecular diagnostics for the water, energy and food & beverage markets, it was also a key supplier of COVID-19 clinical testing reagents to the Government of Canada. Customers in over 80 countries trust LuminUltra’s technology, production reliability and history of customer service excellence to deliver their essential services in a safe-state. At the same time, LuminUltra fosters a culture of innovation and agility and is on an accelerated growth path, acquiring multiple companies in recent years and forming a partnership with the specialized private equity firm XPV Water Partners.
About Genomadix
Based in Ottawa, Canada, Genomadix Inc. is a pioneer in real-time qPCR point of need technology. The Genomadix Cube is a molecular diagnostic instrument capable of performing tests for precision medicine genotyping on a sample-to-result platform. The portable size, ease of use, and on-demand processing capability enables users to generate time-critical results in approximately one hour. The Cube platform is also available as an open platform called CubeX that can be used to design, develop and run any qPCR test for research and product development use. Applications of the Genomadix Cube technology include but are not limited to precision medicine, clinical and environmental. For more information, visit www.genomadix.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240909727336/en/
Contacts
Media: Gene Schilling, Director of Marketing
gene.schilling@luminultra.com +1-519-990-0084
Media: Chelsey Martellacci, Marketing Manager
media@genomadix.com 1-888-810-7788
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Parse Biosciences and Nomic Announce 100 Million Cell, Multimodal AI-ready Dataset for Immune Biology29.10.2026 14:00:00 EET | Press release
Parse Biosciences, the leading provider of scalable and accessible single-cell sequencing and a QIAGEN company, and Nomic Bio, a leader in high throughput proteomic profiling, today announced their partnership to generate Cascade, a 100 Million cell foundational dataset to understand the human immune response. The dataset's scale and depth will give pharma partners cellular- and protein-level insight into immune biology, accelerating their ability to identify and validate new drug targets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261029559438/en/ Cascade has already drawn foundational partner commitments from leading pharmaceutical and biotechnology companies, including GSK, Pfizer, Sanofi, Graph Therapeutics, and Turbine, underscoring the demand for large-scale, multimodal immune data in drug discovery. Cascade is a multimodal, perturbation dataset that captures how immune cells respond to treatment across multiple ti
CSC Named Winner of the Top InfoSec Innovator Award for Most Innovative DNS Security29.10.2026 14:00:00 EET | Press release
CSC, an enterprise-class domain registrar and world leader in mitigating brand, fraud, domain, and Domain Name System (DNS) threats, today announced that its Subdomain Monitoring solution took top honors for Most Innovative DNS Security in Cyber Defense Magazine’s 2026 Top InfoSec Innovator Awards. CSC introduced Subdomain Monitoring after analyzing close to half a million DNS records and finding that many companies were exposed to subdomain takeovers due to dangling DNS. CSC’s solution helps enterprises reduce this risk and secure their online ecosystems. It was the first and only technology on the market to ease the burden of tracking and maintaining DNS records and purging unused zone records to prevent subdomain hijacking. Subdomain Monitoring, powered by CSC’s one-of-a-kind DomainSecSM threat intelligence platform, alerts DNS administrators and security engineers when it detects changes to their zone records. It also provides context on those changes, delivering greater visibility
Two Single-Pill Triple Combination Lipid-Lowering Therapy Applications Validated in The European Union29.10.2026 13:27:00 EET | Press release
The European Medicines Agency (EMA) has validated two marketing authorization applications (MAA) from Daiichi Sankyo (TSE: 4568) for oral, single-pill triple-combination therapies. The applications seek approval for the treatment of adults with primary hypercholesterolemia or mixed dyslipidemia to reduce low-density lipoprotein cholesterol (LDL-C) levels and cardiovascular (CV) risk. Despite the availability of effective therapies, treatment discontinuation remains a persistent challenge in lipid management.1,2 Across both primary and secondary prevention, a significant number of patients at high and very high CV risk do not reach their guideline-recommended LDL-C goals, often due to the complexity and pill burden of taking multiple medications.2 The applications cover two single-pill combinations of three established lipid-lowering agents: bempedoic acid with ezetimibe and atorvastatin, and bempedoic acid with ezetimibe and rosuvastatin.3 Multiple statin dose options of each of these
NIQ and Google Partner to Advance Agentic Commerce29.10.2026 12:45:00 EET | Press release
Today, NielsenIQ (NYSE: NIQ) and Google announced a broad collaboration to advance agentic commerce, aiming to bring NIQ’s global retail and product intelligence together with Google’s AI commerce ecosystem to improve product discovery and local availability. NIQ and Google are looking to complement Google's extensive Shopping Graph of more than 60 billion product listings with NIQ’s Commerce Intelligence. NIQ is also naming Google Cloud as a primary AI and cloud services provider, and plans to deploy Gemini for business across its global workforce. As AI evolves from helping consumers discover products to recommending and purchasing them, brands and retailers increasingly rely on trusted product information, real-world availability, and measurement. The partnership is designed to help make agentic commerce even more reliable and measurable, combining NIQ’s The Full View™ of consumer and retail intelligence with the scale and AI capabilities of Google Cloud and Gemini for business. The
TradeStation Europe Expands Options Capability, Including Extended-Hours Trading29.10.2026 12:43:00 EET | Press release
TradeStation Europe B.V. (“TradeStation Europe”), the recently licensed European brokerage subsidiary of TradeStation Group, Inc. (“TradeStation”), today announced a round of product updates, including extended-hours options trading, along with reduced options and equities pricing, new single-stock option spreads and expanded intraday trading to enhance the offering for retail and institutional traders across the Netherlands and the European Economic Area (EEA). Extended-hours options trading is now live. Clients can trade eligible equity options during a pre-market session from 7:30 a.m. to 9:25 a.m. ET and an extended curb session from 4:00 p.m. to 4:15 p.m. ET. The launch follows Cboe Global Markets, Inc.’s (Cboe: CBOE) introduction of extended trading hours for options on 24 individual stocks and five ETFs, expanding access to some of the most actively traded and liquid single-stock options outside of the regular U.S. trading session. The enhancement expands access beyond tradition
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom